Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to Market
Retrieved on:
Thursday, August 5, 2021
Company, Nature, Research, Addiction, U.S. Securities and Exchange Commission, Maintenance, University of Helsinki, University, Australian dollar, Annual report, Obesity, Exchange, Security (finance), Patient, Limited liability company, Time, Form S-3, Growth, Form, Adenosine, Pain, Communication, Sale, Drinking, Addiction medicine, Opioid use disorder, Gambling, Safety, Marketing, GLOBE, Pharmaceutical industry
In combination with the private placement previously announced on June 3, 2021, this transaction marks the completion of a set of financings totaling $7.1 million.
Key Points:
- In combination with the private placement previously announced on June 3, 2021, this transaction marks the completion of a set of financings totaling $7.1 million.
- William Stilley, Adials Chief Executive Officer, commented, We are pleased to close this last piece of our $7.1 million in private placements, and we appreciate the support of the participating investors.
- Additionally, it is expected to allow us to achieve key milestones for our pre-clinical adenosine program for non-opiate pain relief.
- Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions.